People with Worse Sleep Apnea Have Lower Levels of the Mitochondrial Peptide MOTS-c

This cross-sectional study enrolled 77 participants: 8 with mild OSA, 16 with moderate OSA, 29 with severe OSA, and 24 controls. Serum MOTS-c levels were measured by immunoassay. All participants underwent polysomnography (sleep study) and had complete blood counts, demographic data, and sleep questionnaires collected. Statistical analysis included correlation, ANOVA, and ANCOVA with BMI as covariate.

Sleep apnea affects an estimated 1 billion people worldwide and is linked to metabolic problems, cardiovascular disease, and diabetes. Understanding why metabolic dysfunction occurs in OSA could lead to new treatments. MOTS-c, as an exercise-mimicking mitochondrial peptide, could represent both a biomarker for OSA severity and a potential therapeutic target — supplementing MOTS-c might help counteract the metabolic damage caused by repeated oxygen drops during sleep.

MOTS-c is part of an emerging class of mitochondria-derived peptides (MDPs) that are rewriting our understanding of mitochondria — not just as cellular power plants, but as signaling hubs that communicate with the rest of the body. This study connects MOTS-c to sleep medicine, adding to its known associations with exercise physiology, aging, and metabolic disease. If MOTS-c supplementation proves beneficial, it could address the metabolic complications of OSA without requiring weight loss or continuous positive airway pressure (CPAP).

This is a cross-sectional observational study that cannot establish causation — it's unclear whether low MOTS-c causes OSA-related metabolic problems or is a consequence of them. The sample size of 77 is relatively small, particularly for subgroup analysis by OSA severity. MOTS-c measurement was from a single time point and may not reflect dynamic changes. The study did not assess whether CPAP treatment restores MOTS-c levels. Potential confounders like physical activity level and diet were not controlled.